-
Kataegis in clinical and molecular subgroups of primary breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-04-24 Srinivas Veerla, Johan Staaf
-
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program npj Breast Cancer (IF 5.9) Pub Date : 2024-04-24 Tatjana Geukens, Maxim De Schepper, Wouter Van Den Bogaert, Karen Van Baelen, Marion Maetens, Anirudh Pabba, Amena Mahdami, Sophia Leduc, Edoardo Isnaldi, Ha-Linh Nguyen, Imane Bachir, Maysam Hajipirloo, Gitte Zels, Josephine Van Cauwenberge, Kristien Borremans, Vincent Vandecaveye, Birgit Weynand, Peter Vermeulen, Eleonora Leucci, Maria Francesca Baietti, George Sflomos, Laura Battista, Cathrin Brisken
-
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation npj Breast Cancer (IF 5.9) Pub Date : 2024-04-23 Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte
-
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade npj Breast Cancer (IF 5.9) Pub Date : 2024-04-18 M. C. Liefaard, A. van der Voort, M. van Seijen, B. Thijssen, J. Sanders, S. Vonk, L. Mittempergher, R. Bhaskaran, L. de Munck, A. E. van Leeuwen-Stok, R. Salgado, H. M. Horlings, E. H. Lips, G. S. Sonke
-
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-04-16 Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
-
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-04-11 Yael Bar, Jennifer C. Keenan, Andrzej Niemierko, Arielle J. Medford, Steven J. Isakoff, Leif W. Ellisen, Aditya Bardia, Neelima Vidula
-
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-04-04 Paolo Tarantino, Julieta Leone, Carlos T. Vallejo, Rachel A. Freedman, Adrienne G. Waks, Olga Martínez-Sáez, Ana Garrido-Castro, Filipa Lynce, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney, Jose P. Leone
To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted
-
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-03-29 Roberto A. Leon-Ferre, Jodi M. Carter, David Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, Matthew P. Goetz
Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide systemic treatment, while biomarkers of proliferation have not demonstrated value. Recent studies suggest that subsets of TNBC have a favorable prognosis, even without systemic therapy. We evaluated the association
-
Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-03-26 Amit A. Kulkarni, Aditya Jain, Patricia I. Jewett, Nidhi Desai, Laura Van ’t Veer, Gillian Hirst, Douglas Yee, Anne H. Blaes
-
Reporting on invasive lobular breast cancer in clinical trials: a systematic review npj Breast Cancer (IF 5.9) Pub Date : 2024-03-20 Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, Gabriela Beck, Ann Camden, Megan-Claire Chase, Valerie Fraser, Siobhan Freeney, Laurie Hutcheson, Julia K. Levine, Tone Lien, Rian Terveer, Claire Turner, Elzbieta Senkus, Rachel C. Jankowitz, Vincent Vandecaveye, Giuseppe Floris, Patrick Neven, Hans Wildiers, Elinor Sawyer, Anne Vincent-Salomon, Patrick W. B. Derksen, Christine Desmedt
-
Circulating tumor DNA validity and potential uses in metastatic breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-03-12 Ottavia Amato, Nefeli Giannopoulou, Michail Ignatiadis
-
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-03-12 Han Liu, Liwen Zou, Nan Xu, Haiyun Shen, Yu Zhang, Peng Wan, Baojie Wen, Xiaojing Zhang, Yuhong He, Luying Gui, Wentao Kong
-
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy npj Breast Cancer (IF 5.9) Pub Date : 2024-03-06 Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
-
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays npj Breast Cancer (IF 5.9) Pub Date : 2024-03-04 Reece Foy, Kah Xin Lew, Adrian T. Saurin
-
Deep learning infers clinically relevant protein levels and drug response in breast cancer from unannotated pathology images npj Breast Cancer (IF 5.9) Pub Date : 2024-02-27 Hui Liu, Xiaodong Xie, Bin Wang
-
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis npj Breast Cancer (IF 5.9) Pub Date : 2024-02-26 Silver Alkhafaji, Denise M. Wolf, Mark Jesus M. Magbanua, Laura J. van ‘t Veer, John W. Park, Laura Esserman, Rita A. Mukhtar
-
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study npj Breast Cancer (IF 5.9) Pub Date : 2024-02-24 Jean L. Wright, Robert Gray, Habib Rahbar, Christopher E. Comstock, Judy A. Tjoe, Sunil Badve, Abram Recht, Joseph A. Sparano, Nancy E. Davidson, Antonio C. Wolff
-
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape npj Breast Cancer (IF 5.9) Pub Date : 2024-02-22 Nayan Chaudhary, Alejandro M. Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M. Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
-
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab npj Breast Cancer (IF 5.9) Pub Date : 2024-02-19 Pei Meng, Hina Dalal, Yilun Chen, Christian Brueffer, Sergii Gladchuk, Miguel Alcaide, Anna Ehinger, Lao H. Saal
-
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique npj Breast Cancer (IF 5.9) Pub Date : 2024-01-31 Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan F. Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin H. Kaffenberger, Bernice Y. Kwong, Timothy Pluard, Ruta Rao, Lee Schwartzberg, Michael S. Broder
-
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-01-27 Jie Mei, Yun Cai, Hongjun Zhu, Ying Jiang, Ziyi Fu, Junying Xu, Lingyan Chen, Kai Yang, Jinlu Zhao, Chenghu Song, Yan Zhang, Wenjun Mao, Yongmei Yin
-
A polygenic score associated with fracture risk in breast cancer patients treated with aromatase inhibitors npj Breast Cancer (IF 5.9) Pub Date : 2024-01-20 Christine Hook, Udit Chatterjee, Haiyang Sheng, Qianqian Zhu, Timothy Robinson, Janise M. Roh, Cecile A. Laurent, Catherine Lee, Jennifer Delmerico, Joan C. Lo, Christine B. Ambrosone, Lawrence H. Kushi, Marilyn L. Kwan, Song Yao
-
Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-01-20 L. M. Janssen, M. H. A. Janse, B. B. L. Penning de Vries, B. H. M. van der Velden, E. J. M. Wolters-van der Ben, S. M. van den Bosch, A. Sartori, C. Jovelet, M. J. Agterof, D. Ten Bokkel Huinink, E. W. Bouman-Wammes, P. J. van Diest, E. van der Wall, S. G. Elias, K. G. A. Gilhuijs
-
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation npj Breast Cancer (IF 5.9) Pub Date : 2024-01-18 Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, Bjørn-Erik Bertelsen, Debora Macis, Davide Serrano, Gunnar Mellgren, Matteo Lazzeroni, Parijatham S. Thomas, Katherine D. Crew, Nagi B. Kumar, Irene Maria Briata, Viviana Galimberti, Giuseppe Viale, Lana A. Vornik, Valentina Aristarco, Tania Buttiron Webber, Stefano Spinaci, Powel H. Brown, Brandy M. Heckman-Stoddard, Eva Szabo, Bernardo Bonanni
-
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-01-19 Kelly E. McCann, Shari B. Goldfarb, Tiffany A. Traina, Meredith M. Regan, Neelima Vidula, Virginia Kaklamani
-
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy npj Breast Cancer (IF 5.9) Pub Date : 2024-01-15 Isabelle Grootes, Gordon C. Wishart, Paul David Peter Pharoah
-
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice npj Breast Cancer (IF 5.9) Pub Date : 2024-01-06 Andrea Favero, Ilenia Segatto, Alessandra Capuano, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, Lorena Musco, Sara D’Andrea, Alessandra Dall’Acqua, Chiara Gava, Tiziana Perin, Samuele Massarut, Cristina Marchini, Gustavo Baldassarre, Paola Spessotto, Barbara Belletti
-
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) npj Breast Cancer (IF 5.9) Pub Date : 2024-01-06 Magdalena Mileva, Elisabeth G. E. de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P. Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T. A. Van der Graaf, Wim J. G. Oyen, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Adrienne H. Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart
-
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment npj Breast Cancer (IF 5.9) Pub Date : 2024-01-05 Elena Zaikova, Brian Y. C. Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Tamara Shenkier, Christine Simmons, Sara Taylor, Diego Villa, Ruth Miller, Rosalia Aguirre-Hernandez, Samuel Aparicio, Karen Gelmon
-
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-01-02 Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tolaney, Nancy U. Lin, Deborah A. Dillon, Stuart J. Schnitt, Peter K. Sorger, Elizabeth A. Mittendorf, Sandro Santagata
-
cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2024-01-02 Mengting Chen, Shibo Yu, Tineke van der Sluis, Mieke C. Zwager, Carolien P. Schröder, Bert van der Vegt, Marcel A. T. M. van Vugt
-
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-12-19 Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
-
Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases npj Breast Cancer (IF 5.9) Pub Date : 2023-12-15 Sophia Leduc, Maxim De Schepper, François Richard, Marion Maetens, Anirudh Pabba, Kristien Borremans, Joris Jaekers, Emily Latacz, Gitte Zels, Ali Bohlok, Karen Van Baelen, Ha Linh Nguyen, Tatjana Geukens, Luc Dirix, Denis Larsimont, Sophie Vankerckhove, Eva Santos, Rui Caetano Oliveira, Kristòf Dede, Janina Kulka, Székely Borbala, Ferenc Salamon, Lilla Madaras, A. Marcell Szasz, Valerio Lucidi, Yannick
-
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-12-14 M. Chadha, J. White, S. M. Swain, E. Rakovitch, R. Jagsi, T. Whelan, J. A. Sparano
Older women are under-represented in breast cancer (BC) clinical trials, and treatment guidelines are primarily based on BC studies in younger women. Studies uniformly report an increased incidence of local relapse with omission of breast radiation therapy. Review of the available literature suggests very low rates of distant relapse in women ≥70 years of age. The incremental benefit of endocrine therapy
-
Post-diagnosis weight trajectories and mortality among women with breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-12-02 Leah S. Puklin, Fangyong Li, Brenda Cartmel, Julian Zhao, Tara Sanft, Alexa Lisevick, Eric P. Winer, Maryam Lustberg, Donna Spiegelman, Mona Sharifi, Melinda L. Irwin, Leah M. Ferrucci
-
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets npj Breast Cancer (IF 5.9) Pub Date : 2023-12-02 Lukas Beumers, Efstathios-Iason Vlachavas, Simone Borgoni, Luisa Schwarzmüller, Luca Penso-Dolfin, Birgitta E. Michels, Emre Sofyali, Sara Burmester, Daniela Heiss, Heike Wilhelm, Yosef Yarden, Dominic Helm, Rainer Will, Angela Goncalves, Stefan Wiemann
-
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients npj Breast Cancer (IF 5.9) Pub Date : 2023-11-30 Linda Vidarsdottir, Elinborg J. Olafsdottir, Rosa B. Barkardottir, Olöf Bjarnadottir, Jon G. Jonasson, Stefan Sigurdsson, Laufey Tryggvadottir
-
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation npj Breast Cancer (IF 5.9) Pub Date : 2023-11-30 Rosemary J. Huggins, Geoffrey L. Greene
-
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data npj Breast Cancer (IF 5.9) Pub Date : 2023-11-17 Nancy U. Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram
-
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification npj Breast Cancer (IF 5.9) Pub Date : 2023-11-13 Yao Tian, Lu Zhao, Zhengwei Gui, Shiyang Liu, Chenguang Liu, Tianyao Yu, Lin Zhang
-
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study npj Breast Cancer (IF 5.9) Pub Date : 2023-11-11 Yifeng Shi, Linnea T. Olsson, Katherine A. Hoadley, Benjamin C. Calhoun, J. S. Marron, Joseph Geradts, Marc Niethammer, Melissa A. Troester
-
Prediction models for hormone receptor status in female breast cancer do not extend to males: further evidence of sex-based disparity in breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-11-08 Subarnarekha Chatterji, Jan Moritz Niehues, Marko van Treeck, Chiara Maria Lavinia Loeffler, Oliver Lester Saldanha, Gregory Patrick Veldhuizen, Didem Cifci, Zunamys Itzell Carrero, Rasha Abu-Eid, Valerie Speirs, Jakob Nikolas Kather
-
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-11-01 Susrutha Puthanmadhom Narayanan, Dianxu Ren, Steffi Oesterreich, Adrian V. Lee, Margaret Q. Rosenzweig, Adam M. Brufsky
-
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-10-26 Helena Record, Elle Clelland, Harriet T. Rothschild, Mandeep Kaur, A. Jo Chien, Michelle Melisko, Hope S. Rugo, Firdows Mujir, Laura Huppert, Rita A. Mukhtar
-
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis npj Breast Cancer (IF 5.9) Pub Date : 2023-10-23 Nelson S. Moss, Jolene M. Singh, Anne S. Reiner, Joshua Z. Drago, Shanu Modi, Andrew D. Seidman, Sarat Chandarlapaty, Dara S. Ross
-
TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC npj Breast Cancer (IF 5.9) Pub Date : 2023-10-20 Ning Huang, Peng Li, Xiaolin Sun, Li Tong, Xinyi Dong, Xuemei Zhang, Jifeng Duan, Xia Sheng, Hong Xin
-
Adipose-enriched peri-tumoral stroma, in contrast to myofibroblast-enriched stroma, prognosticates poorer survival in breast cancers npj Breast Cancer (IF 5.9) Pub Date : 2023-10-20 Hannah Si Hui Lau, Veronique Kiak Mien Tan, Benita Kiat Tee Tan, Yirong Sim, Jelmar Quist, Aye Aye Thike, Puay Hoon Tan, Shazib Pervaiz, Anita Grigoriadis, Kanaga Sabapathy
-
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-10-19 Srinivas Veerla, Lennart Hohmann, Deborah F. Nacer, Johan Vallon-Christersson, Johan Staaf
-
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) npj Breast Cancer (IF 5.9) Pub Date : 2023-10-11 Naoki Niikura, Takashi Yamanaka, Hironori Nomura, Kazuhiro Shiraishi, Hiroki Kusama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Yoko Kiga, Tadahiro Izutani, Kazuhito Shiosakai, Junji Tsurutani
-
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study npj Breast Cancer (IF 5.9) Pub Date : 2023-10-06 Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmaña, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
-
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry npj Breast Cancer (IF 5.9) Pub Date : 2023-09-30 Shlomit S. Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Ben-Baruch, Ella Evron, Einav Nili Gal-Yam, Shani Paluch-Shimon, Gil Bar-Sela, Hadar Goldvaser, Salomon M. Stemmer
-
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients npj Breast Cancer (IF 5.9) Pub Date : 2023-09-30 Marjolijn M. Ladan, Titia G. Meijer, Nicole S. Verkaik, Cecile de Monye, Linetta B. Koppert, Esther Oomen-de Hoop, Carolien H. M. van Deurzen, Roland Kanaar, Julie Nonnekens, Dik C. van Gent, Agnes Jager
-
Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants npj Breast Cancer (IF 5.9) Pub Date : 2023-09-29 Anasuya Pal, Laura Gonzalez-Malerva, Seron Eaton, Chenxi Xu, Yining Zhang, Dustin Grief, Lydia Sakala, Lilian Nwekwo, Jia Zeng, Grant Christensen, Chitrak Gupta, Ellen Streitwieser, Abhishek Singharoy, Jin G. Park, Joshua LaBaer
-
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-09-27 Nicola Cosgrove, Alex J. Eustace, Peter O’Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blümel, Darren O’Connor, Sudipto Das, Małgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
-
Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics npj Breast Cancer (IF 5.9) Pub Date : 2023-09-27 Lauren A. Gamble, Paul H. McClelland, Martha E. Teke, Sarah G. Samaranayake, Paul Juneau, Amber L. Famiglietti, Andrew M. Blakely, Bernadette Redd, Jeremy L. Davis
-
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial npj Breast Cancer (IF 5.9) Pub Date : 2023-09-09 Sonja Vliek, Florentine S. Hilbers, Erik van Werkhoven, Ingrid Mandjes, Rob Kessels, Sieta Kleiterp, Esther H. Lips, Lennart Mulder, Mutamba T. Kayembe, Claudette E. Loo, Nicola S. Russell, Marie-Jeanne T. F. D. Vrancken Peeters, Marjo J. Holtkamp, Margaret Schot, Joke W. Baars, Aafke H. Honkoop, Annelie J. E. Vulink, Alex L. T. Imholz, Suzan Vrijaldenhoven, Franchette W. P. J. van den Berkmortel,
-
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-09-08 Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli
-
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-09-08 Jun Ma, Jack Junjie Chan, Ching Han Toh, Yoon-Sim Yap
-
Deep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-08-30 Sangjoon Choi, Soo Ick Cho, Wonkyung Jung, Taebum Lee, Su Jin Choi, Sanghoon Song, Gahee Park, Seonwook Park, Minuk Ma, Sérgio Pereira, Donggeun Yoo, Seunghwan Shin, Chan-Young Ock, Seokhwi Kim
-
Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer npj Breast Cancer (IF 5.9) Pub Date : 2023-08-19 Paul E. Hanna, Ian A. Strohbehn, Daiana Moreno, Destiny Harden, Rituvanthikaa Seethapathy, Rani Sawtell, Qiyu Wang, Tianqi Ouyang, Nurit Katz-Agranov, James Dinulos, Seth A. Wander, Shruti Gupta, Meghan E. Sise